AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Mar 28, 2025

Contemporary controversies in bladder cancer management

During the established format of rapid-fire debates, International Bladder Cancer Group (IBCG) members from around the globe will present both sides of current issues, ensuring a diverse range of perspectives and expertise.


Ashish Kamat, MD
Ashish Kamat, MD

What is the clinical utility of integrating artificial intelligence (AI) in pathology and its potential impact on diagnostic accuracy and bladder cancer risk assessment? How does Bacillus Calmette-Guerin (BCG) therapy compare to emerging treatment modalities within the content of personalized medicine? What is the optimal treatment sequencing for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who decline radical cystectomy?

Those are just a few of the hot topics that will be debated during the “AUA-IBCG Bladder Cancer Forum: Common Problems and Controversies in Bladder Cancer” at the 2025 AUA Annual Meeting.

During the established format of rapid-fire debates, International Bladder Cancer Group (IBCG) members from around the globe will present both sides of a current issue, ensuring a diverse range of perspectives and expertise.

“We’ve selected controversial, yet relevant, topics on bladder cancer management that are seen in day-to-day clinical practice. They’re common topics where patients seek definitive answers, but current guidelines offer limited or conflicting solutions,” said Ashish Kamat, MD, IBCG president and professor of urologic oncology at the University of Texas MD Anderson Cancer Center in Houston, who will co-chair the forum with Kelly Bree, MD, assistant professor of urology, also with MD Anderson Cancer Center.

In addition to AI, emerging treatment modalities and treatment sequencing for patients with BCG-unresponsive NMIBC, other topics on this year’s debate agenda that were the most requested based on attendee feedback at last year’s AUA Annual Meeting, include:

  • Standardizing transurethral resection of bladder tumor (TURBT): Which factors influence optimal TURBT technique? “The TURBT is paramount in patient management, as it establishes the foundational understanding of the tumor necessary for subsequent treatment decisions,” Dr. Kamat said.
  • When is active surveillance in low-grade intermediate-risk bladder cancer appropriate?
  • Who is the right patient for trimodal therapy (TMT) in muscle-invasive bladder cancer (MIBC)? This session will feature the president of the American Society for Radiation Oncology (ASTRO), Neha Vapiwala, MD, a radiation oncologist at Penn Medicine, as a featured guest speaker.
  • What is the clinical utility of circulating tumor DNA (ctDNA) in adjuvant therapy decisions and when it is most appropriate?
  • Bladder preservation following neoadjuvant chemotherapy: Are bladder preservation protocols ready for widespread clinical adoption in patients exhibiting complete clinical response to neoadjuvant chemotherapy?

Be prepared to gain a comprehensive overview of current controversies and emerging evidence in bladder cancer management and a clear understanding of the pros and cons of different strategies for enhancing clinical decision-making.

“We are now confronted with a veritable abundance of emerging technologies and therapeutic modalities, which, while undoubtedly beneficial, have resulted in a landscape that can be perceived as rather confusing,” Dr. Kamat said. “Navigating that abundance requires clarity, which we hope this session will provide."

Interesting Stories
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
More Content
Getty Images 1971521073 (2)
Previews
P2s spotlight groundbreaking clinical trials
Apr 15, 2025
Young Res
Previews
Resident programming fosters skills, camaraderie and leadership
Apr 15, 2025
Akanksha Mehta, MD, MS
Previews
Panel to explore updated vasectomy guidelines
Apr 15, 2025
Melissa R. Kaufman, MD, PhD, FACS
Previews
New guidelines for managing genitourinary syndrome of menopause
Apr 15, 2025
Getty Images 2197045271
Previews
AUA2025 will offer a glimpse into the future of urology
Mar 28, 2025
Patient Perspectives
Previews
Shining a light on Patient Perspectives
Mar 28, 2025
Li-Ming Su, MD
Previews
Crossfire to explore single versus multiport robotic surgery
Mar 28, 2025
Daniel W. Lin, MD
AUA2023
Experts to debate best uses of PSMA-PET in prostate cancer treatment decisions
Apr 07, 2023
Bowl Winners 02
AUA2023
AUA2023 Annual Meeting in pictures
Apr 07, 2023
Getty Images 1344701426
AUA2023
Residents Forum explores career possibilities in urology
Apr 07, 2023
Getty Images 1438547233
AUA2023
Supporting inclusivity and encouraging diversity in urology
Apr 07, 2023
Getty Images 530686149
AUA2023
Keep your career flow going
Apr 07, 2023
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.